Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.64 |
| ▸ | CSF1R | P07333 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353946 | 0.87 | CSF1R (0.80) | EGFRCSF1RCYP1A2CYP3A4CLK4 | |
| SCHEMBL4353312 | 0.83 | CYP1A2 (0.75) | CYP1A2CYP3A4CLK4MAPK1LMNA | |
| SCHEMBL4355365 | 0.81 | CSF1R (0.73) | EGFRCSF1RCYP1A2CYP3A4LMNA | |
| SCHEMBL4353556 | 0.81 | ADORA2A (0.48) | EGFRMAP4K4 | |
| SCHEMBL4350161 | 0.80 | EGFR (0.56) | EGFRCSF1RCYP1A2CYP3A4CLK4 | |
| SCHEMBL4354965 | 0.78 | EGFR (0.70) | EGFRCSF1RLMNAALDH1A1MEN1 | |
| SCHEMBL3112161 | 0.78 | EGFR (1.00) | EGFRCSF1RPDGFRBPDGFRA | |
| SCHEMBL3123760 | 0.78 | CSF1R (1.00) | EGFRCSF1RLMNAPDGFRBPDGFRA | |
| SCHEMBL8897798 | 0.77 | MAP4K4 (0.58) | EGFRCSF1RCYP1A2CYP3A4CLK4 | |
| Hydrochloric Acid SCHEMBL8165127 | 0.77 | CSF1R (0.97) | EGFRCSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | EGFR 2581/4885CSF1R 1495/4885CYP1A2 1131/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | EGFR 1831/4885CSF1R 1158/4885CYP1A2 1129/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | EGFR 1826/4885CSF1R 1289/4885CYP1A2 1078/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | EGFR 1826/4885CSF1R 1289/4885CYP1A2 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.